Investigating interactions between epicardial adipose tissue and cardiac myocytes: what can we learn from different approaches?

How to cite:

For guidance on citations see FAQs.

© 2016 The British Pharmacological Society

Version: Accepted Manuscript

Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1111/bph.13678

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies page.
Investigating interactions between epicardial adipose tissue and cardiac myocytes: what can we learn from different approaches?

Katja Rietdorf and Hilary MacQueen

School of Life, Health and Chemical Sciences
The Open University
Milton Keynes, MK7 6AA, UK

Katja.Rietdorf@open.ac.uk
Hilary.MacQueen@open.ac.uk

Key words: epicardial adipose tissue, cardiac myocytes, adipokines, 3D co-culture
Abstract

Heart disease is a major cause of morbidity and mortality throughout the world. Some cardiovascular conditions can be modulated by lifestyle factors such as increased exercise or a healthier diet, but many require surgical or pharmacological interventions for their management. More targeted and less invasive therapies would be beneficial. Recently it has become apparent that epicardial adipose tissue plays an important role in normal and pathological cardiac function, and it is now the focus of considerable research. Epicardial adipose tissue can be studied by imaging of various kinds, and these approaches have yielded much useful information. However at a molecular level it is more difficult to study as it is relatively scarce in animal models and, for practical and ethical reasons, not always available in sufficient quantities from patients. What is needed is a robust model system in which the interactions between epicardial adipocytes and cardiac myocytes can be studied, and physiologically relevant manipulations performed. There are drawbacks to conventional culture methods, not least the difficulty of culturing both cardiac myocytes and adipocytes, each of which has special requirements. We discuss the benefits of a three-dimensional co-culture model in which in vivo interactions can be replicated.
**Non-Standard abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D</td>
<td>2 dimensional</td>
</tr>
<tr>
<td>3D</td>
<td>3-dimensional</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CT</td>
<td>computer tomography</td>
</tr>
<tr>
<td>EAT</td>
<td>epicardial adipose tissue</td>
</tr>
<tr>
<td>EC-coupling</td>
<td>excitation-contraction coupling</td>
</tr>
<tr>
<td>FABP4</td>
<td>fatty-acid binding protein 4</td>
</tr>
<tr>
<td>FDG-PET</td>
<td>fluoro-deoxyglucose PET</td>
</tr>
<tr>
<td>FFA</td>
<td>free fatty acid</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>PET-CT</td>
<td>positron-emission computer tomography</td>
</tr>
<tr>
<td>RyR</td>
<td>ryanodine receptor</td>
</tr>
<tr>
<td>SAT</td>
<td>superficial adipose tissue</td>
</tr>
<tr>
<td>SR</td>
<td>sarcoplasmic reticulum</td>
</tr>
<tr>
<td>TAG</td>
<td>triacylglycerols</td>
</tr>
</tbody>
</table>
Introduction

The mammalian heart is surrounded by layers of visceral fat known as paracardial adipose tissue. The outermost layer of adipose tissue, the pericardial layer, can cover the entire structure and is separated from the surface of the heart by a layer of connective tissue, the fascia. Beneath this fascia, however, is another layer of fat that is directly apposed onto the heart, with no physical barrier between the two: the epicardial adipose tissue (EAT, see figure 1). EAT is located primarily around cardiac blood vessels, in the atrio-ventricular cleft, and around the right ventricle; it can also extend into the myocardium and this is not in itself indicative of disease (Rabkin, 2007). Post-mortem studies have shown that EAT can cover 80% of the heart and contribute up to 20% of ventricular mass in normal individuals (Rabkin, 2007; Chechi et al., 2015). Epicardial adipocytes have many characteristics of white adipocytes, but produce UCP-1, a marker characteristic of brown adipocytes (Nicholls et al., 1978; Sacks et al., 2009; Sacks et al., 2013). Thus some authors have described this tissue as ‘beige’ or ‘brite’ (Gaborit et al., 2013; Chechi et al., 2015).

The functional relationship between the heart and the overlying EAT is important; indeed the adipocytes within EAT, and their products, are critical to the function of the heart. Epicardial adipocytes are an essential source of free fatty acids, which cardiac myocytes preferentially utilise for energy (Marchington et al., 1989). EAT also provides thermal and physical protection for the heart (Rabkin, 2007; Chechi et al., 2015), and, importantly, is a rich source of adipokines which can interact with cardiac myocytes and other tissues in a paracrine manner to promote efficient cardiac function (Talman et al., 2014). However, these beneficial functions of EAT can be diminished or negated by the release of signals that evoke pathological changes in coronary blood vessels and cardiac myocytes. Thus there is interest in investigating interactions between EAT and the heart. Such studies could identify
clinically relevant processes or molecules that might allow pharmacological interventions for a range of cardiovascular diseases.

Considerable work has shown that adipose tissue is biochemically specialised in a site-specific way relating to its function (MacQueen et al., 2000; Mattacks et al., 2004; Westcott et al., 2006; Pond, 2009). There are clear and consistent differences in the triacylglycerol fatty acids found in adipocytes from different anatomical locations, even within the same adipose depot. Therefore it is not surprising that patterns of gene expression and proteins secreted also differ between adipocytes in a site-specific way. Zdychova et al. (2014) studied the secretome of adipocytes explanted and cultured from EAT, renal adipose tissue and superficial adipose tissue (SAT). Mazurek et al. (2003) were the first to show differences in cytokines secreted by EAT in patients with coronary artery disease (CAD), and found a higher number of pro-inflammatory cytokines secreted by the EAT. Compared to SAT, the transcriptome of the EAT is typical of that from an inflammatory tissue (McAninch et al., 2015). Not only are the secretome and transcriptome different between SAT and EAT: Gaborit et al. (2015) have recently characterised molecular differences between various regions of the EAT (peri-ventricular, peri-coronary and peri-atrial). In general, pathological conditions such as CAD result in a downregulation of genes involved in intracellular trafficking, proliferation and protein catabolism, and an upregulation of genes involved in inflammatory and immune responses.

**The structure and function of EAT**

Epicardial fat is present from birth in humans and its mass increases with age until between 20 and 40 years of age after which time it becomes independent of age (Rabkin, 2007). It is a dynamic fat depot, and can increase, or remodel, in conditions such as obesity and
inflammation (Hassan et al., 2012; Iacobellis, 2015; Kusayama et al., 2015; McAninch et al., 2015; Matloch et al., 2016; Samanta et al., 2016). During development EAT arises from the splanchnopleural mesodermal lineage, the same origin as mesenteric and omental fat (Marchington et al., 1989; Gaborit et al., 2013), and it therefore shares the same lineage as cardiac myocytes (Martinsen et al., 2005). The two tissues are closely related in that they share circulation and innervation (Marchington et al., 1989; Arora et al., 2003). Intrinsic cardiac neurons and ganglionated plexuses, containing adrenergic and cholinergic neurons, are embedded in EAT (Arora et al., 2003; White, 2016). Zhou et al. (2014) showed that the cardiac ganglionated plexus in EAT incorporates the autonomic innervation (both sympathetic and parasympathetic) of the heart, and affects atrial function. Moreover, Balcioglu et al. (2015) found that a sympathovagal imbalance, a predictor of arrhythmia, was associated with EAT thickness. Parisi et al. (2016) also found that in patients with heart failure there was cardiac sympathetic denervation that could be correlated with increased epicardial adipocyte volume. EAT is not just a passive supporting structure for cardiac innervation, but is innervated in its own right. Zeng et al. (2015) have shown, although not in epicardial adipocytes, that sympathetic innervation of adipose tissue mediates the lipolytic action of leptin. Adipocytes from many sources have been shown to be sensitive to both β- and α- adrenergic stimulation, which directly increase lipolysis (Mattacks et al., 1999; Mattacks et al., 2005) thus providing an increased supply of free fatty acids for the heart’s energy requirements (see above).

The thickness of EAT is a predictor for several types of cardiovascular disease signs such as stenosis, calcification, atheroma, stiffness, plaque development and arrhythmias including atrial fibrillation (Mookadam et al., 2010; Hassan et al., 2012; Gaborit et al., 2013; Hatem et al., 2014; Furuhashi et al., 2016; Siegel-Axel et al., 2016; Wong et al., 2016). Moreover
increased EAT volume is associated with a lengthened PR interval (Hung et al., 2015), suggesting that EAT can interfere with electrical conduction through the heart. Recently cognitive decline and dementia have also been linked to an increased EAT thickness (Mazzoccoli et al., 2014; Viscogliosi et al., 2016). However, EAT thickness varies between ethnicities, so no specific threshold value for clinical significance has yet been established (Willens et al., 2008; Pierdomenico et al., 2013; Yañez-Rivera et al., 2014). The relative amount of EAT varies between species. In general, larger mammals have more prominent EAT than smaller animals like rodents (Marchington et al., 1989). Recent studies have shown that mice possess a limited amount of EAT, located in the atrio-ventricular groove (Yamaguchi et al., 2015). Nevertheless it is difficult to obtain large amounts of EAT from rodents, limiting their use as a source of tissue for \textit{ex vivo} and \textit{in vitro} investigations.

In common with other visceral fat depots, EAT has a function in lipid trafficking, and its mass is correlated with whole-body adiposity (Iacobellis et al., 2004). However, the mean adipocyte volume is around half the value found in other visceral adipose depots (Marchington et al., 1989) suggesting that the primary function of epicardial adipocytes is not fat storage. Moreover, even though the adipocytes in EAT can take up fatty acids from the circulation, convert them to triacylglycerols (TAG), and subsequently lipolyse and release them, these processes are not regulated by insulin in the same way as in adipocytes from other depots (Burgeiro et al., 2016): epicardial adipocytes are specialised for their role supporting heart muscle (Marchington et al., 1990). EAT is not simply a benign store of excess fat, since it is metabolically active and interacts with surrounding tissues, including the contractile cardiac myocytes within the heart (Gaborit et al., 2013). It is this last point that is the focus of our work, as we seek to understand how the metabolic activities of epicardial adipocytes support, or in pathological conditions dysregulate, cardiac myocyte function. The
metabolic cross-talk between EAT and the myocardium is poorly understood; nevertheless there is compelling evidence that it exists and is important in health and disease. Glucose uptake and lipid metabolism in EAT have been shown to be impaired in patients with heart failure, and these effects are modulated in patients who also had diabetes (Burgeiro et al., 2016). There is a growing body of evidence of changes in gene expression in EAT that can be linked to cardiovascular disease (Salgado-Somoza et al., 2012; Agra et al., 2014a; Agra et al., 2014b). This topic is extensive and has recently been systematically reviewed by Maghbooli et al. (2015). These authors concluded that the ‘hub’ genes for EAT involvement in cardiovascular disease were IL6 and p53; the latter gene was also identified as of major importance in coronary artery disease (Agra et al., 2014b).

Like other cells that have a high demand for fatty acids (such as T cells containing a Gall body) cardiac myocytes contain fat droplets (Iozzo, 2011). It is thought that this sequestration of fatty acids allows them to be used rapidly when a physiological need arises. The particular mix of fatty acids sequestered varies with cell type and anatomical site (MacQueen et al., 2000; Pezeshkian et al., 2009; Pond, 2009), and it would be interesting to measure the particular fatty acid mix found within cardiac myocytes and compare it with the fatty acid profiles of EAT. Burgeiro et al. (2016) reported that the fatty acid composition of epicardial adipocytes is altered in patients with heart failure and diabetes, and this might suggest the existence of related changes in the fatty acid composition of cardiac myocytes in pathological states.

**Overview of adipokines**

It is well known that adipocytes secrete signalling molecules, and other factors that affect the cardiovascular system. Adipokines are frequently measured in the general circulation
EAT and cardiac myocytes

(reviewed by Iacobellis, 2015) but these measurements cannot address the paracrine interactions that take place at a local level. It is not yet clear which of the cohort of paracrine messengers cause particular pathological changes in cardiac myocytes. Moreover, it has been demonstrated that the secretome of adipocytes can change under pathological conditions such as inflammation, thereby promoting the release of harmful signals (Kusayama et al., 2015; Venteclief et al., 2015; Furuhashi et al., 2016; Iacobellis, 2016). Adipokines have been linked to many pathologies (Deng et al., 2010b) but the mechanisms involved remain to be elucidated.

The in vivo effects of adipokines are complex and not easily predictable. For example, the effects can be dose- or concentration-dependent, or may only become obvious if a particular combination of adipokines is present. As an example, the cardioprotective effect of omentin-1 only becomes obvious when cardiac function is impaired, such as in diabetes mellitus (Greulich et al., 2013). Interestingly, the baseline adiponectin concentration in EAT is lower than that found in other fat depots (Elie et al., 2016), yet adiponectin can partially rescue the diminished cardiac contraction observed in obese mice (Dong et al., 2009). Both omentin-1 and adiponectin are considered to be cardioprotective not only because of their direct effects on cardiac myocytes, but also because they reduce inflammation, improve endothelial function, and reduce oxidative stress (Gaborit et al., 2015; Matloch et al., 2016). The cardioprotective function of adrenomedullin is thought to originate in its vasodilative, anti-inflammatory, and anti-oxidative effects, and in its inhibition of hypertrophic remodelling in a disease situation (Silaghi et al., 2007; Fosshaug et al., 2015). Some adipokines, such as resistin, activin A and FABP4 (Lamounier-Zepter et al., 2009; Look et al., 2011; Venteclief et al., 2015) have detrimental effects, whilst others, such as leptin and apelin, can show either helpful or deleterious effects depending on their concentration (Look et al., 2011; Ghantous...
et al., 2015). As well as acting on myocytes, some adipokines have been shown to have an effect on cardiovascular endothelia: for example orosomucoid can increase proliferation in endothelial cells and therefore promotes healing of damaged endothelia (Fandino-Vaquero et al., 2014). It is unclear what provokes changes in the secretome of EAT to tip the balance between release of deleterious versus beneficial signals. However Fernandez- trasancos et al. (2016) showed in vitro that inflammatory conditions, and glucose levels, affected adiponectin expression in EAT. The reported effects of a number of adipokines are summarised in Table 1.

**EATing for a healthy heart**

EAT is critical for the function of a healthy heart by supplying free fatty acids (FFA) as the preferred energy source for cardiac myocytes, and by acting as a sink in case of an excess of circulating FFA. Nevertheless, much research has established that through its secretion of pro-inflammatory adipokines EAT is significantly associated with coronary artery disease and atherosclerosis (Shimabukuro et al., 2013; Talman et al., 2014; Furuhashi et al., 2016). In fact, EAT around the coronary vessels can co-localise with areas of plaque development (Prati et al., 2003; Alexopoulos et al., 2010). Peri-corporal EAT shows an upregulation of genes regulating sphingosine metabolism, suggesting a role for EAT in atherogenesis (Gaborit et al., 2015). While it is clear that compromised blood supply can interfere with heart function, our interest lies more with possible direct effects of EAT and its adipokines on the cardiac myocytes, and the disruption to regular beating that can result in arrhythmias such as atrial fibrillation.

As noted above, EAT is a dynamic depot and its size is positively correlated with whole-body fat and obesity. Interestingly, changes in the structure and function of cardiac myocytes, and
EAT and cardiac myocytes

the pro-inflammatory status of the adipocytes caused by a high fat diet can precede the onset of weight gain and obesity (Goncalves et al., 2016), and during weight loss protocols EAT reduces in thickness before abdominal fat is reduced (Iacobellis, 2015). This suggests that EAT activity is highly sensitive to nutritional status, and that epicardial adipocytes may act as a sentinel for cardiac dysfunction.

Throughout a typical human lifetime the heart beats 2 million times (Bers, 2002). The contraction of the heart is triggered by action potentials that propagate from the sino-atrial node in the right atrial chamber. As an action potential sweeps across the atrial and ventricular chambers it causes the membrane to depolarise, thus opening voltage-operated calcium (Ca^{2+}) channels and causing a Ca^{2+} influx into the cell. Within the cell, this Ca^{2+} signal is amplified by Ca^{2+}-induced Ca^{2+} release via ryanodine receptors (RyRs) on the sarcoplasmic reticulum (SR), thus causing a global Ca^{2+} signal that triggers the intracellular contractile machinery to engage, so that the cells shorten and generate the force to propel blood to the lungs and body. This process is often referred to as excitation-contraction coupling (EC-coupling; Berridge, 2003; Dobrzynski et al., 2013) and is illustrated in Figure 2.

For a regular heartbeat, each action potential must cause a rapid, transient, Ca^{2+} rise within every cardiac myocyte. It is believed that increased automaticity (spontaneous depolarisation of myocytes), acute triggered activity (spontaneous electrical events following recovery from an action potential) or re-entry circuits (return of an electrical impulse to cardiac cells following a refractory period) contribute to the development of arrhythmia. The underlying causes of all these pro-arrhythmic conditions are not fully understood, but substantial evidence has implicated a higher incidence of spontaneous Ca^{2+} signals as a likely cause.
EAT and cardiac myocytes

(Bers, 2008; Heijman et al., 2012; Voigt et al., 2012). Generally, pro-arrhythmic processes can be classified into electrical and structural remodelling. Electrical remodelling encompasses changes in the ion channel expression, changing the myocyte’s response to action potentials and leading to automaticity and triggered activity. Electrical remodelling can occur very rapidly, and is usually reversible. Recent evidence suggests that FFA can cause electrical remodelling in the atria (O’Connell et al., 2015). In contrast, structural remodelling takes longer to develop, and is usually irreversible. The most common structural remodelling process is fibrosis, the formation of fibrotic tissue between cardiac myocytes. As a consequence of fibrosis, the propagation of electrical signals is disrupted because of the presence of non-conducting tissue. Instead of propagating into the next cell, electrical signals spread sideways or backwards and can enter the same cell again, leading to the development of perpetuating rotors of electrical signals, and consequently to arrhythmia (Eisner, 2014; Heijman et al., 2014; Lip et al., 2016). Of interest here is the fatty infiltration between the cardiac myocytes, seen when excess EAT is present, that can transform into fibrotic tissue; adipokines and cytokines secreted from EAT can induce fibrosis (Haemers et al., 2015; Venteclef et al., 2015) and alter the Ca^{2+} handling, and thus the contractions, of cardiac myocytes (Hatem et al., 2016). It appears that the correct functioning of EAT is essential for effective cardiovascular activity, and the interactions between EAT and cardiac myocytes represent an important therapeutic target.

Approaches to studying EAT

EAT has historically been a somewhat neglected tissue (Rabkin, 2007) but the advent of techniques such as echocardiography made it easy to identify and quantify. Extensive work by Iacobellis and others (Iacobellis et al., 2003; Iacobellis et al., 2005; Iacobellis et al., 2009b; Iacobellis et al., 2009a; McAninch et al., 2015; Elisha et al., 2016) showed that EAT
varies between individuals in thickness and volume, and the thickness can be correlated with
disease states. For example, there is significantly more EAT in subjects with metabolic
syndrome or coronary artery disease than in those without these conditions (Sade et al., 2009;
Pierdomenico et al., 2013). The advantage of echocardiography is that it is non-invasive
(though it may be coupled with more invasive techniques such as angiography), relatively
cheap and widely available (Parisi et al., 2016); its disadvantage is that the studies are
observational, giving a ‘snapshot’ of patients who have already presented with a suspected or
actual cardiopathology. Also, using this technique it can be difficult to define the border
between epicardial and pericardial fat, which can potentially generate misleading data (Hatem
et al., 2016). Other fat depots which would be useful as controls are located in different parts
of the body, so the appropriate controls can usually not be obtained from the same patient due
to the increased risks and length of the necessary surgery (Fain et al., 2010; Gaborit et al.,
2015). One of the few prospective studies undertaken so far reported a correlation of peri-
atrial EAT thickness with the future onset of AF in patients who did not show any signs of
AF at the time of the scan (Nakanishi et al., 2012). The reproducibility of echocardiographic
analysis and interpretation has been questioned (Wong et al., 2016); nevertheless good
correlation between echocardiography and other techniques for measuring EAT thickness in
specific areas has been reported (Song do et al., 2015).

Other types of imaging studies have been undertaken, such as computed tomography (CT)
(Sarin et al., 2008; den Dekker et al., 2014; Harada et al., 2014; Hung et al., 2015; Kitagawa
et al., 2015), positron-emission CT (PET-CT) (Janik et al., 2010; Bakkum et al., 2015),
magnetic resonance imaging (MRI) (Kim et al., 2012; Gaborit et al., 2013; Hua et al., 2014)
and FDG-PET (fluoro-deoxyglucose PET) (Kaushik et al., 2014; Mazurek et al., 2014). The
principal advantage of all these methods is that they are non-invasive, and there is generally
EAT and cardiac myocytes

much better resolution than in echocardiographic studies. Three-dimensional and volume measurements, rather than simply thickness, are possible: both CT and MRI can specifically measure peri-coronary EAT, which is an important correlate of atherosclerosis (Iacobellis, 2016; Wong et al., 2016). CT studies have confirmed an association between atherosclerosis, myocardial infarction and EAT (Mahabadi et al., 2013; Mahabadi et al., 2014). However CT uses radiation, so is not suitable for follow-up studies requiring repeated measurements. The main drawback of these techniques is that they require expensive equipment and are neither cheap nor easy to access. This is particularly the case for cardiac MRI, regarded as the gold standard because it gives good 3D imaging, does not use radiation, and is the only method to have been verified ex vivo. MRI can reliably detect fibrosis and fat depots (Wong et al., 2016). Therefore there is a trade-off between availability and accuracy when considering imaging methods.

Post-mortem examination of patients who have died from other causes can provide some indications of the situation in ‘normal’ (albeit dead) individuals (Gho et al., 2014; Furuhashi et al., 2016). A drawback to post-mortem studies is that the condition that killed the individual may itself have affected adipose tissue distribution, giving some uncertainty as to what actually constitutes ‘normal’. Even when samples can be obtained from live patients, they are usually small and may allow only the analysis of mRNA levels, not the actual expressed protein levels. For ethical reasons it is currently difficult to obtain control patients, although this may change with the advent of large-scale prospective studies.

Going beyond the identification and quantitation of EAT, many studies of the depot have involved molecular and biochemical studies using either blood or tissue biopsies, obtained during elective cardiovascular surgery procedures. These studies have variously used ELISA (Mazurek et al., 2003; Gao et al., 2011; Sacks et al., 2011; Teijeira-Fernandez et al., 2011;
Fosshaug et al., 2015; Venteclef et al., 2015; Elie et al., 2016), PCR (Mazurek et al., 2003; Fain et al., 2010; Gao et al., 2011; Teijeira-Fernandez et al., 2011; Fosshaug et al., 2015), miR analysis (Vacca et al., 2016), transcriptome and secretome analysis (Guauque-Olarte et al., 2011; Imoto-Tsubakimoto et al., 2013; Gaborit et al., 2015; McAninch et al., 2015; Venteclef et al., 2015) to show that the molecular profile of EAT is different from that of other adipose depots, and can change during physiological challenges affecting the heart. This large body of data supports the site-specific, localised role played by EAT, but does not elucidate the question of whether the observed changes are the cause or the effect of physiological disturbance. In order to get around this problem a model system amenable to experimental manipulation is required. Although clinicians are frequently unwilling to translate data derived from animal studies to humans, it remains the case that whole animals, or cells derived from them, constitute a rich source of information and data, and can frequently provide valid experimental models. We discuss some of the options below.

**Studying EAT-cardiac myocyte interactions using animal models**

Some of the earliest studies of EAT (Marchington et al., 1989; Marchington et al., 1990) used short-term cultures of tissue explants from rodents to study the biochemistry and fat trafficking in epicardial adipocytes. Animal tissue has also been cultured for this purpose by Greulich et al. (2011) (guinea pigs and rats), Chilukoti et al. (2015) (pigs and rats), and Lage et al. (2015) (neonatal rats and cell lines). The availability of a range of mouse knock-out strains has also been exploited by Nevelsteen et al. (2013), studying cardiac myocyte function and obesity, though not specifically EAT, and by Castro et al. (2015). This group reported on a wide-ranging project in which they studied the metabolomics by MS-NMR and looked at circadian rhythms of brown and white adipose tissue.
In an attempt to elucidate the role of adipokines in cardiac dysfunction, many *in vitro* studies have added purified adipokines to cardiac myocytes in culture, and measured the effects on their function. A drawback of these studies is that the adipokine effects may be complex and are often concentration-dependent (see above): for example the cardioprotective effect of omentin-1 is only evident when applied in combination with inflammatory interleukins (Greulich *et al.*, 2013). It is not easy to replicate in culture relevant physiological conditions, in which there may be subtle differences in adipokine and other cytokine concentrations. One approach to resolving this problem has been to use *ex vivo* cultured EAT biopsy samples to prepare conditioned media for adding to established cultures of (usually) rodent cardiac myocytes. Such an approach has been used to analyse the secretome, and to test for structural and functional effects of the EAT on the cardiac myocytes. Such studies identified activin A as the major factor causing fibrosis (Venteclef *et al.*, 2015).

It is known that both a high fat diet and diabetes mellitus cause deterioration in heart function. Medium conditioned by the EAT of animals eating a high fat diet recapitulated these effects (reduced contraction strength and Ca\(^{2+}\) amplitude in isolated rat cardiac myocytes), whilst medium conditioned by SAT did not (Greulich *et al.*, 2011). In a later study, the authors found that the reduced cardiac function was caused by a lack of omentin-1, which in healthy animals protects the cardiac myocytes from the detrimental effects of cytokines like interleukins. Omentin-1 cannot fulfil this function when its levels are reduced in diabetes mellitus type 2 (Greulich *et al.*, 2013). Other cardioprotective effects of omentin-1 have been mentioned in Table 1. Another adipokine that impairs cardiac function, specifically the cardiac myocyte’s contractility, is FABP4, which was identified and its effects characterised by Lamounier-Zepter *et al.* (2009 and 2014). The detrimental effects of FABP4
are potentiated in the presence of epoxyeicosatrienoic acids, which are also secreted by the EAT.

Although many such studies have elucidated the role of EAT and related it to cardiac function, little has yet been done to elucidate the physiological interplay between these tissues. In order to do this rigorously a culture methodology that is robust, reproducible and physiologically relevant must be adopted. Conventional two-dimensional (2D) culture can be, and has been, used but although it offers the opportunity for extensive experimental manipulations it is a poor representation of the in vivo physiological situation. Whilst a cardiac myocyte culture, using neonatal cells, is relatively straightforward to set up, it is difficult to mimic any effects of neighbouring adipocytes. Using adipocyte-conditioned media, as described above, means that cardiac myocytes are presented with a bolus of adipocyte-derived molecules, which, although more representative than the addition of isolated adipokines, are nevertheless likely to be at different concentrations from those present in the paracrine flow that occurs in vivo. In addition, labile molecules will not be adequately represented in conditioned medium, so their effects can be missed. From a clinical perspective it is necessary to find treatments that allow the long-term management of adipocyte-cardiac myocyte interactions. Acute responses evoked by bolus additions of adipocyte-conditioned medium can pinpoint factors that affect cardiac myocyte function, but it is not a method that allows prolonged study, and management, of cardiac myocyte functionality and viability in the presence of persistent paracrine signals. For these reasons, we consider that a better method for studying interactions between cell types may be to use three-dimensional (3D) co-cultures, and we elaborate on this below.

The 3D approach
Primary adipocytes are difficult to work with in vitro, as they are very fragile. They cannot be retained in 2D cultures because their buoyant density decreases as they accumulate triacylglycerols, causing them to detach from the culture substrate and become lost during medium changes. Furthermore, only cardiac myocytes prepared from neonatal rodents can be kept in culture for prolonged periods of time, as cardiac myocytes isolated from adult animals de-differentiate quickly after being isolated and placed in 2D culture. However in 3D culture it is possible to keep cardiac myocytes differentiated and spontaneously beating for a period of up to 6 weeks (Burridge et al., 2014). Their phenotype resembles that of a mature differentiated myocyte when they are kept in a 3D culture that has a stiffness mimicking that of the heart (Engler et al., 2008; Pontes Soares et al., 2012; Bian et al., 2014). Similarly, adipocytes show good survival in 3D cultures, and retain the in vivo structural and functional characteristics of mature adipocytes (Daya et al., 2007). Because collagen gels are translucent, 3D co-cultures are amenable to microscopic analyses that allow real-time measurement of cellular responses and phenotype. Contractions of the whole gel or of cells inside the gel can be measured by force transducers or by visualising cell contraction, and intracellular Ca\textsuperscript{2+} changes can be monitored using fluorescent Ca\textsuperscript{2+} sensitive dyes (Shapira-Schweitzer et al., 2009; Ye, 2011; Bian et al., 2014; Chiu et al., 2014). Furthermore, the culture supernatants can be assayed for secreted molecules, and the two cell types can be independently recovered for proteomic, genomic and molecular analysis (Daya et al., 2007; Phillips et al., 2011; Georgiou et al., 2015). Thus primary cardiac myocytes and adipocytes can be co-cultured for prolonged periods of time, allowing paracrine signalling to occur, and the interactions between these cells to become established in a way that closely models the in vivo situation. The functionality and viability of cells within the 3D collagen matrix can be closely monitored, and both cell types can be recovered separately for subsequent in vitro molecular analysis. By culturing adipocytes and cardiac myocytes within a 3D co-culture
EAT and cardiac myocytes

model we can better mimic the normal concentrations and rates of paracrine delivery of signals between these cells.

**Conclusions**

Epicardial adipose tissue is now well established as an important modulator of cardiac function. Changes in EAT metabolism can be associated with a number of pathologies both in human patients and in animal models, and it seems clear that this relationship is a strong candidate for therapeutic intervention. However the relationship is a complex one: not only does the particular mix of paracrine signals vary with physiological state, but the anatomical location within the EAT appears to play a part as well. Like all adipose tissue, EAT demonstrates site-specific functionality.

Although there have been many important contributions towards elucidating the interplay between cardiac myocytes and EAT, more questions remain unanswered. Key to identifying the underlying mechanism(s) is the deployment of appropriate experimental techniques that will allow experimental manipulation of the relationship over the short and medium term. Only then will it be apparent whether the changes seen in EAT metabolic activities are the cause or the result of the pathologies. Current technologies range from the ‘snapshots’ provided by imaging and analysis of biopsy samples from patients through to highly reductionist *in vitro* techniques. One limitation of human studies will always be the lack of ‘healthy EAT’ samples as a control. Our preference is to develop a 3D co-culture system in which both cardiac myocytes and adipocytes can flourish together over several weeks, and in which experimental modifications and subsequent analysis are straightforward.

**Author contributions**

The authors contributed equally to this work.
Acknowledgements

Our work has been funded by the BBSRC, the British Heart Foundation, and The Open University.

Conflicts of interest

The authors declare no conflicts of interest.
EAT and cardiac myocytes

References


Bakkum MJ, Danad I, Romijn MA, Stuijfzand WJ, Leonora RM, Tulevski, II, *et al.* (2015). The impact of obesity on the relationship between epicardial adipose tissue, left ventricular...


EAT and cardiac myocytes


EAT and cardiac myocytes


EAT and cardiac myocytes


Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. *Hormone and Metabolic Research* 41: 227-231.


Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of
EAT and cardiac myocytes


The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine 12: 1395-1403.


EAT and cardiac myocytes


Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DT (2014).

Epicardial adipose tissue: far more than a fat depot. *Cardiovascular Diagnosis and Therapy* 4: 416-429.


**Table 1 Cardiovascular effects of adipocytokines secreted by EAT.** This table summarises publications describing effects of adipokines secreted from EAT. +, positive effects; ±, positive and negative effects; -, negative effects on cardiovascular function. [Please also see separate document for the table in landscape format, our preferred formatting option.]

<table>
<thead>
<tr>
<th>Name</th>
<th>Observation</th>
<th>Methodology</th>
<th>Overall effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>General inflammatory adipokines</td>
<td>EAT secretes pro-inflammatory cytokines (TNFα, MCP1, IL-1, IL-1β, IL-1Ra, IL-6, IL-8, PAI-1, CRP, haptoglobin) which are all linked to coronary artery disease (CAD). NFκB upregulated in inflammatory states</td>
<td>Review articles.</td>
<td>-</td>
<td>(Mazurek et al., 2003) (Gaborit et al., 2013)</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>Improves endothelial function via endothelial NO synthase (eNOS)</td>
<td>Isolated aortic tissue from rats on normal vs. high fat diet. Adiponectin addition. eNOS and iNOS responses in vascular tissue were characterised. Responses of rat aortic tissue and human aortic endothelial cells to adiponectin addition were characterised (endothelial function, eNOS).</td>
<td>+</td>
<td>(Li et al., 2007) (Deng et al., 2010a)</td>
</tr>
<tr>
<td></td>
<td>In obesity, reduces oxidative stress, further protecting the endothelium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Improves the redox state in blood vessels by restoration of eNOS coupling</td>
<td>Human adipose tissue samples (perivascular, subcutaneous and mesothoracic), endothelium from matching vein and arteries. Adiponectin</td>
<td>+</td>
<td>(Margaritis et al., 2013)</td>
</tr>
<tr>
<td><strong>EAT and cardiac myocytes</strong></td>
<td>gene expression and vascular responses to eNOS were characterised.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td><strong>Decreased levels in obesity</strong></td>
<td>Abdominal and epicardial adipose tissue from humans. CT study in humans (atherosclerosis patients). Adipokine plasma levels were measured.</td>
<td>-</td>
<td>(Cheng et al., 2008)</td>
<td></td>
</tr>
<tr>
<td><strong>Recombinant adiponectin can successfully reverse some harmful effects of EAT-derived factors</strong></td>
<td>EAT samples from human CAD patients ± diabetes. Conditioned medium, effects on THP-1 cells and endothelial cells were characterised.</td>
<td>+</td>
<td>(Karastergiou et al., 2010)</td>
<td></td>
</tr>
<tr>
<td><strong>Generally cardioprotective, downregulated in CAD and heart failure</strong></td>
<td>Review article</td>
<td>±</td>
<td>(Iacobellis, 2015)</td>
<td></td>
</tr>
<tr>
<td><strong>Decreased in CAD</strong></td>
<td>Review article</td>
<td>-</td>
<td>(Gaborit et al., 2013)</td>
<td></td>
</tr>
<tr>
<td><strong>Possible negative effects in elderly heart-failure patients</strong></td>
<td>Isolated cardiac myocytes from LepR&lt;sup&gt;db/db&lt;/sup&gt; mice &amp; lean control mice. Responses to adiponectin.</td>
<td>+</td>
<td>(Dong et al., 2009)</td>
<td></td>
</tr>
<tr>
<td><strong>Rescues reduced contractility, reduces the speed of contraction and increases peak Ca&lt;sup&gt;2+&lt;/sup&gt; in cardiac myocytes from LepR&lt;sup&gt;db/db&lt;/sup&gt; mice. No effects on lean control mice</strong></td>
<td>In vitro co-culture of adipocytes and macrophages from ob/ob mice, high fat diet and control mice; EPA treatment. Adiponectin concentration in human plasma from obese patients, ± EAT.</td>
<td>-</td>
<td>(Itoh et al., 2007)</td>
<td></td>
</tr>
<tr>
<td><strong>Reduced secretion in presence of macrophages, except in the presence of EPA</strong></td>
<td>Whole rat hearts, Langendorff prep. Conditioned medium from isolated adipocytes and pure cytokines. Effects on contractility.</td>
<td>+</td>
<td>(Look et al., 2011)</td>
<td></td>
</tr>
<tr>
<td><strong>Anti-hypertrophic</strong></td>
<td>Human periaortic, pericoronary and apical EAT samples. Adipokine expression.</td>
<td>+</td>
<td>(Spiroglou et al., 2010)</td>
<td></td>
</tr>
<tr>
<td><strong>Inversely correlated with atherosclerosis</strong></td>
<td>Isolated rat cardiac myocytes, FABP4 effects on myocyte function. Isolated rat cardiac myocytes. Adipocyte conditioned medium. Addition of isolated 5,6-EET and FABP4; effects on cardiac function.</td>
<td>-</td>
<td>(Lamounier-Zepter et al., 2009)</td>
<td></td>
</tr>
<tr>
<td><strong>FABP4</strong></td>
<td>Human obese patients ± left ventricular dysfunction. Adipokine levels and ventricular diastolic function measured.</td>
<td>-</td>
<td>(Baessler et al., 2014)</td>
<td></td>
</tr>
<tr>
<td><strong>Suppresses cardiac myocyte contractions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Associated with left ventricular dysfunction in obese subjects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### EAT and cardiac myocytes

<table>
<thead>
<tr>
<th>Adrenergic Medullin</th>
<th>Pro-fibrotic</th>
<th>Pro-inflamatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced mRNA and protein levels in CAD</td>
<td>Upregulated in animals eating a high fat diet</td>
<td>Suppresses cardiac myocyte function; intracellular uptake of FA and intracellular transport; upregulated in EAT from patients with metabolic syndrome</td>
</tr>
<tr>
<td>Increased mRNA in patients with CAD</td>
<td>Pro-inflammatory</td>
<td>Review article.</td>
</tr>
<tr>
<td>Increased levels in EAT but not SAT from heart failure patients</td>
<td>-</td>
<td>EAT and ascending aorta tissue samples from human metabolic syndrome patients. FABP4 expression.</td>
</tr>
<tr>
<td>Adrenomedullin</td>
<td>-</td>
<td>(Xu et al., 2012)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Vural et al., 2008)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Fosshaug et al., 2015)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Lamounier-Zepter et al., 2009)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Venteclef et al., 2015)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Greulich et al., 2011)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Hatem, 2014)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Hatem et al., 2014)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Greulich et al., 2012)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Venteclef et al., 2015)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Silaghi et al., 2007)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Jacobellis et al., 2009a)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Shibasaki et al., 2010)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>(Fosshaug et al., 2015)</td>
</tr>
<tr>
<td>Adipokine</td>
<td>Effect</td>
<td>Context</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Omentin-1</strong></td>
<td>Anti-inflammatory and promotes insulin sensitivity. Improves endothelial function, and reperfusion after ischaemia, by increasing the production of nitric oxide by eNOS.</td>
<td>Human EAT and SAT samples, gene expression was characterised.</td>
</tr>
<tr>
<td>Plasma level decreases in obesity and in type 2 diabetes.</td>
<td>EAT biopsies from human diabetes mellitus patients and controls used to create conditioned medium. Omentin-1 levels and effects on contractile function and insulin secretion in rat cardiac myocytes were measured.</td>
<td>+ (Greulich et al., 2013)</td>
</tr>
<tr>
<td>mRNA and protein expression increased in patients with CAD, particularly from EAT around areas of stenosis.</td>
<td>Plasma, SAT and EAT samples in human CAD patients and controls. Adipokine levels were measured.</td>
<td>(Du et al., 2016)</td>
</tr>
<tr>
<td><strong>Leptin</strong></td>
<td>Reduces endothelial-dependent vasodilation</td>
<td>Rat, leptin effects on blood pressure were characterised.</td>
</tr>
<tr>
<td>Increased in obesity</td>
<td>Abdominal and epicardial adipose tissue from human atherosclerosis patients. CT study; plasma levels of adipokines were measured.</td>
<td>- (Cheng et al., 2008) (Greif et al., 2009)</td>
</tr>
<tr>
<td>Chemo attractive to monocytes</td>
<td>THP-1 macrophages from LepR\textsuperscript{db/db} and LepR\textsuperscript{+/+} mice. Responses to purified leptin and MCP-1 were characterised.</td>
<td>- (Gruen et al., 2007)</td>
</tr>
<tr>
<td>Decreases high density lipoproteins and apolipoprotein A\textsubscript{1} concentrations</td>
<td>Correlation of leptin and HDL levels in healthy humans.</td>
<td>- (Rainwater et al., 1997)</td>
</tr>
<tr>
<td>Activates C-reactive protein (CRP) and serum amyloid A</td>
<td>Correlation study of BMI and serum adipokine levels in healthy humans.</td>
<td>- (Kazumi et al., 2003)</td>
</tr>
<tr>
<td>Increases oxidative stress, inflammation and smooth muscle proliferation, recruits monocytes and via macrophages accelerates the formation of foam cells</td>
<td>Review article</td>
<td>- (Matloch et al., 2016)</td>
</tr>
<tr>
<td>Rapidly induces hypertrophy in cultured neonatal rat ventricular myocytes</td>
<td>Neonatal rat ventricular myocytes. Leptin addition. Measurement of hypertrophy.</td>
<td>- (Rajapurohitam et al., 2003)</td>
</tr>
<tr>
<td>Increases blood pressure and heart rate via sympathetic nervous system stimulation and causes hypertension</td>
<td>Fasting leptin plasma levels in humans with hypertension were measured.</td>
<td>- (Paiolloso et al., 1999)</td>
</tr>
<tr>
<td>Physiological doses abolish the negative</td>
<td>Rat models of ischemia/reperfusion injury</td>
<td>+ (Smith et al., 2010)</td>
</tr>
</tbody>
</table>
### EAT and cardiac myocytes

<table>
<thead>
<tr>
<th>Effect</th>
<th>Description</th>
<th>Methodology</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inotropic effects of IL-1β and can protect from reperfusion injury</td>
<td>Leptin administration were examined.</td>
<td>-</td>
<td>(Beltowski et al., 2004)</td>
</tr>
<tr>
<td>Reduce endothelial-dependent vasodilation</td>
<td>Rat, leptin effects on blood pressure were measured.</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Resistin</td>
<td>Circulating levels increased in obesity Abdominal and epicardial adipose tissue from human atherosclerosis patients.</td>
<td>Abdominal and epicardial adipose tissue from human atherosclerosis patients. Plasma adipokine levels were measured.</td>
<td>(Cheng et al., 2008)</td>
</tr>
<tr>
<td>Promotes cardiac hypertrophy in rodents</td>
<td>Neonatal rat ventricular myocytes and adult rat cardiac myocytes. Resistin overexpression. Cardiac function and signalling pathways were examined.</td>
<td>Human rat ventricular myocytes and adult rat cardiac myocytes. Resistin overexpression. Cardiac function and signalling pathways were examined.</td>
<td>(Kim et al., 2008)</td>
</tr>
<tr>
<td>Impairs endothelial function</td>
<td>Review article</td>
<td>-</td>
<td>(Pang et al., 2006)</td>
</tr>
<tr>
<td>Increased circulating levels in heart failure and myocardial infarction</td>
<td>Human myocardial infarction, ischemic stroke patients and controls. Plasma resistin levels were measured. Human HF patients, adipokine levels in blood samples were measured.</td>
<td>Human myocardial infarction, ischemic stroke patients and controls. Plasma resistin levels were measured. Human HF patients, adipokine levels in blood samples were measured.</td>
<td>(Weikert et al., 2008) (Frankel et al., 2009)</td>
</tr>
<tr>
<td>Associated with atherosclerosis, myocardial infarction and coronary artery disease</td>
<td>Adipokine secretion in EAT from human acute coronary syndrome vs. CAD patients. Human myocardial infarction patients. Blood, EAT and SAT samples. Resistin levels were measured.</td>
<td>Adipokine secretion in EAT from human acute coronary syndrome vs. CAD patients. Human myocardial infarction patients. Blood, EAT and SAT samples. Resistin levels were measured.</td>
<td>(Langheim et al., 2010) (Rachwalik et al., 2014)</td>
</tr>
<tr>
<td>Apelin</td>
<td>Positive inotropic effect in normal and failing myocardium. Protective against ischemia and reperfusion injury in rats</td>
<td>Rat hearts, pressure overload models and isolated neonatal rat ventricular myocytes. Apelin effects on cardiac function were measured. Iscemic reperfusion injury rat model, effects of apelin addition were examined. Heart failure control rats, cardiac function after apelin addition was characterised.</td>
<td>(Szokodi, 2002) (Berry et al., 2004) (Kleinz et al., 2008)</td>
</tr>
<tr>
<td>Positively correlated with obesity; promotes a cardioprotective response</td>
<td>Apelin-receptor KO mice, characterisation of cardiac function.</td>
<td>+</td>
<td>(Scimia et al., 2012)</td>
</tr>
<tr>
<td>Stimulates contractility in cardiac myocytes</td>
<td>Rat hearts, pressure overload models and neonatal rat ventricular myocytes. Apelin effects on cardiac function were examined.</td>
<td>+</td>
<td>(Szokodi, 2002)</td>
</tr>
</tbody>
</table>
### Exogenous apelin has anti-inflammatory effects and reduces the formation of aortic aneurisms

- Mouse aortic aneurysm model ± apelin. Adipokine expression in macrophages, smooth muscle cells and fibroblasts was measured.  
  +  
  (Leeper et al., 2009)

### Vaspin

- Correlated with atherosclerosis in a site-specific way  
  Human periaortic, pericoronary and apical EAT samples. Adipokine expression was measured.  
  -  
  (Spiroglou et al., 2010)

### Circulating levels correlated with reduced cardiac flow reserve

- Human nonalcoholic fatty liver disease patients. Measurement of EAT thickness, coronary flow reserve and chemerin and vaspin serum levels.  
  -  
  (Yilmaz et al., 2011)

### Visfatin

- Site-specific expression within EAT, increased in patients with atherosclerosis  
  Human periaortic, pericoronary and apical EAT samples. Adipokine expression was measured.  
  -  
  (Spiroglou et al., 2010)

### Proinflammatory; produces endothelial dysfunction

- Human diabetes patients and controls. Plasma visfatin levels. Endothelial function was measured.  
  -  
  (Takebayashi et al., 2007)

### Exogenous visfatin reduces cell death and myocardial infarct size after reperfusion

- Mouse ischemia/reperfusion injury model ± visfatin. Isolated myocytes in hypoxia ± visfatin. Signalling pathways and mitochondrial function were measured.  
  +  
  (Lim et al., 2008)

### Chemerin

- Positive correlation with atherosclerosis  
  Human periaortic, pericoronary and apical EAT samples. Adipokine expression was measured.  
  -  
  (Spiroglou et al., 2010)

### mRNA and protein expression increased in patients with CAD

- EAT and SAT and serum samples from human CAD patients and controls. Adipokine levels were measured.  
  -  
  (Gao et al., 2011)

### Induces apoptosis in mouse cardiac myocytes in culture

- Mouse cardiac myocytes; insulin and TNF-α treatment. CMKLR1 and chemerin expression were measured.  
  -  
  (Rodriguez-Penas et al., 2015)

### Orosomucoid

- At low levels, orosomucoid secretion from EAT protects cultured cardiac myocytes from apoptosis due to hypoxia  
  At high levels orosomucoid is a risk factor for myocardial infarction and heart failure.  
  EAT samples from human biopsies were used to prepare conditioned medium. Rat cardiac myocyte cell line (H9C2) and neonatal rat ventricular myocytes. Effects on cell viability ± hypoxia were measured.  
  ±  
  (Lage et al., 2015)

### Increasing endothelial cell proliferation, promotes healing of damaged endothelia

- EAT and SAT samples from type 2 diabetes mellitus patients used to prepare conditioned medium. Adipokine secretion after isoproterenol stimulation and effects of conditioned medium measured on endothelial cell function and  
  +  
  (Fandino-Vaquero et al., 2014)
EAT and cardiac myocytes

wound healing were measured.
<table>
<thead>
<tr>
<th>Ligands</th>
<th>Targets</th>
<th>Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptin</td>
<td></td>
<td>Adiponectin receptor</td>
</tr>
<tr>
<td>FABP4</td>
<td></td>
<td>Fatty acid-binding proteins</td>
</tr>
<tr>
<td>Adiponectin</td>
<td></td>
<td>Adrenomedullin - human</td>
</tr>
<tr>
<td>FABP3</td>
<td></td>
<td>Adrenomedullin - mouse</td>
</tr>
<tr>
<td>Chemerin</td>
<td></td>
<td>Chemerin receptor</td>
</tr>
<tr>
<td>5,6-EET</td>
<td></td>
<td>Adrenomedullin - rat</td>
</tr>
<tr>
<td></td>
<td>Leptin receptor</td>
<td>Adiponectin receptor</td>
</tr>
<tr>
<td></td>
<td>Apelin receptor</td>
<td>Fatty acid-binding proteins</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adrenomedullin - human</td>
</tr>
<tr>
<td></td>
<td>Adipo1 receptor</td>
<td>Adrenomedullin - mouse</td>
</tr>
<tr>
<td></td>
<td>Chemerin receptor</td>
<td>Adrenomedullin - rat</td>
</tr>
<tr>
<td></td>
<td>Adipo2 receptor</td>
<td>Adiponectin receptor</td>
</tr>
</tbody>
</table>
Figure 1 Diagram illustrating the positions of epicardial and pericardial fat depots in the heart. Note the intimate association between the epicardial fat and the myocardium.


Figure 2 Model of potential interactions between cardiac excitation-contraction coupling and EAT. The figure illustrates places where adipokines might affect the excitation-contraction coupling of cardiac myocytes. Panel A shows the excitation-contraction coupling in cardiac myocytes in a healthy situation. Arrival of an action potential (ΔVM) opens voltage-gated Ca2+ channels in the sarcolemma, causing the influx of Ca2+ ions. The increase in the intracellular Ca2+ concentration activates Ca2+-activated Ca2+...
release via ryanodine receptors localised on the sarcoplasmic reticulum (SR), causing the myocyte to contract. Adipocytes in the EAT are in contact with the cardiac myocytes, and can reach between them. They secrete e.g. omentin-1, apelin and adiponectin, which act on the cardiac myocytes in a positive manner, sustaining their regular contractions. They also affect processes other than the myocyte’s contraction, e.g. gene expression, anti-inflammatory functions, and protection from reactive oxygen species (ROS). Panel B shows changes occurring in a disease situation, where the secretome from the EAT is remodelled. Adipocytes infiltrate deeper between the myocytes and release different adipokines, e.g. activin A, leptin and FABP4. Activin A activates fibrosis, which in turn hinders the smooth propagation of action potentials and can cause pro-arrhythmic re-entry circuits. FABP4 and apelin reduce the myocyte’s contraction strength. Adipokines can increase intracellular ROS production, causing spontaneous Ca\(^{2+}\) release from the SR, further contributing to arrhythmia. Adipokines in a diseased state cause a pro-inflammatory situation, including the recruitment and activation of macrophages, and change the pattern of gene expression. Several of the signalling pathways and receptors activated by adipokines are not yet identified.